Gamma Oryzanol Treats Obesity-Induced Kidney Injuries by Modulating the Adiponectin Receptor 2/PPAR-α Axis

Area of Science:

• Nephrology
• Metabolic Syndrome Research
• Nutritional Biochemistry

Background:

• Obesity and metabolic syndrome (MetS) pose significant risks for chronic kidney disease (CKD) by impairing renal function and homeostasis.
• Dietary factors and metabolic disturbances contribute to kidney damage.
• Gamma oryzanol (γOz) exhibits antioxidant and anti-inflammatory properties, with demonstrated benefits in obesity and metabolic disorders.

Purpose of the Study:

• To investigate the renoprotective effects of γOz in a rat model of diet-induced obesity and metabolic syndrome.
• To determine if γOz can restore renal function by modulating the adiponectin receptor 2/PPAR-α signaling pathway.

Main Methods:

• Male Wistar rats were fed a high sugar-fat (HSF) diet for 20 weeks to induce obesity and renal dysfunction.
• Animals with detected proteinuria were treated with γOz or continued on the HSF diet for an additional 10 weeks.
• Evaluations included nutritional and biochemical parameters, blood pressure, renal function, kidney inflammation, oxidative stress markers, and protein expression of adiponectin receptor 2 and PPAR-α via Western blot.

Main Results:

• γOz treatment significantly improved renal function and reduced inflammation in HSF-fed rats.
• Antioxidant enzyme activities were increased, and oxidative stress markers were decreased following γOz administration.
• Protein expression of adiponectin receptor 2 and PPAR-α was upregulated by γOz treatment.

Conclusions:

• γOz effectively ameliorates obesity-induced kidney disease in rats.
• The renoprotective effects of γOz are attributed to its ability to modulate the PPAR-α pathway, reduce inflammation, and combat oxidative stress.